MichaelR.GreverMD

Professor of Medicine, Ohio State University

Dr. Grever is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-7677

Fax+1 614-293-5614

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1976 - 1978
UPMC Medical EducationResidency, Internal Medicine, 1971 - 1974
University of Pittsburgh School of MedicineClass of 1971

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

6376 citations
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis, Izidore S. Lossos, Andreas Rosenwald
Nature. 2000-02-03
8 citations
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine P...
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao
The Oncologist. 2020-08-01
277 citations
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly
Journal of Clinical Oncology. 2017-02-13

Abstracts/Posters

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Challenges In Management Of Hairy Cell Leukemia In 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Phase I Trials Of Anti-Cancer AgentsNational Cancer Institute2003–2012
Pre-Clinical And Clinical Development Of Silvestrol In Chronic LymphocyticNational Cancer Institute2009–2011
Par04-122, Extramural Research Facilities Improvement P*National Center For Research Resources2010
Signal Transduction And Kinase Inhibition In CLLNational Cancer Institute2006–2010
Molecular Studies Of Drug Resistance In Chronic LymphocyNational Cancer Institute2000–2003
Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2002
Phase II Clinical Trials ConsortiumNational Cancer Institute1994–2000
Phase II Study Of 9-Aminocamptothecin In Chronic Lymphocytic LeukemiaNational Center For Research Resources1997–1999
CalgbNational Cancer Institute1998
Southwest Oncology GroupNational Cancer Institute1985–1997
Oncology Training GrantNational Cancer Institute1985–1997
Core--Interdisciplinary Oncology UnitNational Cancer Institute1985–1994
OncologyNational Cancer Institute1988–1992
Deoxycoformycin In Lymphoid MalignanciesNational Cancer Institute1985–1986